肥胖与代谢性疾病的联合治疗
Combination therapy for obesity and metabolic disease.
作者信息
Gadde Kishore M, Allison David B
机构信息
Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, North Carolina 27710, USA.
出版信息
Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):353-8. doi: 10.1097/MED.0b013e3283304f90.
PURPOSE OF REVIEW
There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases.
RECENT FINDINGS
Emerging data from recently completed and ongoing randomized clinical trials suggest that certain combination-drug therapies in development have greater efficacy than currently available single-drug therapies in terms of achieved weight loss and reduction in risk factors.
SUMMARY
Combination-drug therapy may have a role in the treatment of obesity and related diseases as well as for prevention of risk factors. As we await safety data from studies with larger samples, the demonstrated efficacy of some of the combination drug therapies in late-stage development appears to be robust and clinically meaningful.
综述目的
开发用于治疗和管理肥胖症及相关代谢疾病的联合疗法正受到越来越多的关注。
最新发现
近期完成和正在进行的随机临床试验的新数据表明，某些正在研发的联合药物疗法在实现体重减轻和降低风险因素方面比目前可用的单一药物疗法具有更高的疗效。
总结
联合药物疗法可能在肥胖症及相关疾病的治疗以及危险因素的预防中发挥作用。在我们等待更大样本量研究的安全性数据时，一些处于后期研发阶段的联合药物疗法所显示出的疗效似乎很显著且具有临床意义。
Zotero 插件